Factors Associated With Delayed and Late Initiation of Antiretroviral Therapy Among Patients With HIV in Beijing, China, 2010-2020. 2023

Yuanqi Mi, and Mengge Zhou, and Yuhong Zeng, and Peicheng Wang, and Liangmin Gao, and Feng Cheng
Department of Epidemiology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, United States.

Objectives: To determine factors associated with late and delayed antiretroviral therapy (ART) initiation in China and provide evidence for HIV prevention. Methods: Logistics regression model was used to determine factors associated with three outcomes: late (CD4 cell count <200 cells/µL or clinical AIDS diagnosis prior to ART initiation), delayed (more than 1 month between HIV diagnosis date and ART initiation) and either late or delayed ART initiation. Results: Multivariable analysis revealed that male, heterosexual, HIV diagnosis before 2014, HBV/HCV seropositive, and tuberculosis were associated with increased odds of all three outcomes. Conversely, married or cohabiting patients were less likely to have delayed ART initiation and either late or delayed ART initiation, while people who inject drugs were more likely to have these two outcomes. Additionally, older age was associated with an increased risk of having either late or delayed ART initiation, but a decreased risk of delayed ART initiation. Conclusion: The proportion of late and delayed ART initiation decreased significantly after the release of the 2016 guidelines in China. To further improve late diagnosis and early treatment, precise interventions for key populations are required.

UI MeSH Term Description Entries
D008297 Male Males
D002681 China A country spanning from central Asia to the Pacific Ocean. Inner Mongolia,Manchuria,People's Republic of China,Sinkiang,Mainland China
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000068476 Beijing Capital of CHINA. Peking
D015658 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human
D044966 Anti-Retroviral Agents Agents used to treat RETROVIRIDAE INFECTIONS. Antiretroviral Agent,Antiretroviral Agents,Agent, Antiretroviral,Agents, Anti-Retroviral,Agents, Antiretroviral,Anti Retroviral Agents
D057210 Delayed Diagnosis Non-optimal interval of time between onset of symptoms, identification, and initiation of treatment. Diagnosis Delay,Late Diagnosis,Delayed Diagnoses,Diagnosis Delays,Diagnosis, Delayed,Diagnosis, Late,Late Diagnoses
D018791 CD4 Lymphocyte Count The number of CD4-POSITIVE T-LYMPHOCYTES per unit volume of BLOOD. Determination requires the use of a fluorescence-activated flow cytometer. Lymphocyte Count, CD4,T4 Lymphocyte Count,CD4 Cell Counts,CD4 Counts,CD4+ Cell Counts,CD4+ Counts,CD4 Cell Count,CD4 Count,CD4 Lymphocyte Counts,CD4+ Cell Count,CD4+ Count,Count, T4 Lymphocyte,Counts, T4 Lymphocyte,Lymphocyte Count, T4,Lymphocyte Counts, CD4,Lymphocyte Counts, T4,T4 Lymphocyte Counts
D019380 Anti-HIV Agents Agents used to treat AIDS and/or stop the spread of the HIV infection. These do not include drugs used to treat symptoms or opportunistic infections associated with AIDS. AIDS Drug,AIDS Drugs,Anti-AIDS Agents,Anti-AIDS Drug,Anti-HIV Agent,Anti-HIV Drug,Anti-AIDS Drugs,Anti-HIV Drugs,Agent, Anti-HIV,Agents, Anti-AIDS,Agents, Anti-HIV,Anti AIDS Agents,Anti AIDS Drug,Anti AIDS Drugs,Anti HIV Agent,Anti HIV Agents,Anti HIV Drug,Anti HIV Drugs,Drug, AIDS,Drug, Anti-AIDS,Drug, Anti-HIV,Drugs, AIDS,Drugs, Anti-AIDS,Drugs, Anti-HIV
D023241 Antiretroviral Therapy, Highly Active Drug regimens, for patients with HIV INFECTIONS, that aggressively suppress HIV replication. The regimens usually involve administration of three or more different drugs including a protease inhibitor. Combination Antiretroviral Therapy,HAART,Highly Active Antiretroviral Therapy,Antiretroviral Therapies, Combination,Antiretroviral Therapy, Combination,Combination Antiretroviral Therapies,Therapies, Combination Antiretroviral,Therapy, Combination Antiretroviral

Related Publications

Yuanqi Mi, and Mengge Zhou, and Yuhong Zeng, and Peicheng Wang, and Liangmin Gao, and Feng Cheng
January 2017, PloS one,
Yuanqi Mi, and Mengge Zhou, and Yuhong Zeng, and Peicheng Wang, and Liangmin Gao, and Feng Cheng
January 2012, PloS one,
Yuanqi Mi, and Mengge Zhou, and Yuhong Zeng, and Peicheng Wang, and Liangmin Gao, and Feng Cheng
January 2023, Journal of medical virology,
Yuanqi Mi, and Mengge Zhou, and Yuhong Zeng, and Peicheng Wang, and Liangmin Gao, and Feng Cheng
August 2017, Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine],
Yuanqi Mi, and Mengge Zhou, and Yuhong Zeng, and Peicheng Wang, and Liangmin Gao, and Feng Cheng
January 2024, Scientific reports,
Yuanqi Mi, and Mengge Zhou, and Yuhong Zeng, and Peicheng Wang, and Liangmin Gao, and Feng Cheng
January 2014, Journal of the International AIDS Society,
Yuanqi Mi, and Mengge Zhou, and Yuhong Zeng, and Peicheng Wang, and Liangmin Gao, and Feng Cheng
December 2007, AIDS (London, England),
Yuanqi Mi, and Mengge Zhou, and Yuhong Zeng, and Peicheng Wang, and Liangmin Gao, and Feng Cheng
December 2023, AIDS patient care and STDs,
Yuanqi Mi, and Mengge Zhou, and Yuhong Zeng, and Peicheng Wang, and Liangmin Gao, and Feng Cheng
January 2022, Frontiers in public health,
Yuanqi Mi, and Mengge Zhou, and Yuhong Zeng, and Peicheng Wang, and Liangmin Gao, and Feng Cheng
January 2020, HIV/AIDS (Auckland, N.Z.),
Copied contents to your clipboard!